KRAS+ Non-Small Cell Lung Cancer
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
Dr. Manochakian discusses the most pressing unanswered questions in lung cancer and how they could be addressed.
Dr. Manochakian shared his insights during the Oncology Brothers Advancements in Oncology event.
Dr. Manochakian discusses new data and why next-generation sequencing is a critical step when treating NSCLC.
Researchers examined the demographic and clinical outcomes in patients with KRAS-mutated tumors, using patients with NSCLC.
Patients of Hispanic/Latino ethnicity have a greater prevalence of certain lung cancer driver mutations.
Advertisement
Expert Interviews
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.